| Stage | CAH | % of rev | MCK | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $63.7B | 100.00% | $105B | 100.00% | MCK ×1.66 |
| Gross profit | $2.6B | 4.02% | $3.7B | 3.50% | CAH +0.5pp |
| Operating income | $729M | 1.14% | $1.3B | 1.25% | MCK +0.1pp |
| Pre-tax income | $554M | 0.87% | $1.3B | 1.24% | MCK +0.4pp |
| Net income | $400M | 0.63% | $1.0B | 0.98% | MCK +0.4pp |
| Stage | CAH | MCK | Gap · A − B |
|---|---|---|---|
| Revenue | $63.7B100.00% | $105B100.00% | MCK ×1.66 |
| Gross profit | 4.02%$2.6B | 3.50%$3.7B | CAH +0.5pp |
| Operating income | 1.14%$729M | 1.25%$1.3B | MCK +0.1pp |
| Pre-tax income | 0.87%$554M | 1.24%$1.3B | MCK +0.4pp |
| Net income |
| 0.63%$400M |
| 0.98%$1.0B |
| MCK +0.4pp |
CAH 10-KAug 12 '25
“Our largest customer, CVS Health, accounted for 30 percent of our fiscal 2025 revenue.”
MCK 10-KMay 9 '25
“Sales to our largest customer, CVS Health Corporation ("CVS"), accounted for approximately 24% of our total consolidated revenues in fiscal 2025 and comprised approximately 23% of total trade accounts receivable at March 31, 2025.”
CAH · LLY 10-KFeb 12 '26
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
MCK · LLY 10-KFeb 12 '26
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
CAH · ABBV 10-KFeb 20 '26
“In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States.”
MCK · ABBV 10-KFeb 20 '26
“In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States.”
CAH · GILD 10-KFeb 28 '25
“Cardinal Health, Inc. 26 % 26 % 25 %”
MCK · GILD 10-KFeb 28 '25
“McKesson Corporation 20 % 21 % 20 %”
CAH · VTRS 10-KFeb 27 '25
“Cardinal Health, Inc. * 5 % 5 %”
MCK · VTRS 10-KFeb 27 '25
“McKesson Corporation * 10 % 11 %”
CAH · SUPN 10-KFeb 25 '25
“Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 20% of our total product revenue in 2024 and collectively accounted for more than 77% of our total product revenue in 2024.”
MCK · SUPN 10-KFeb 25 '25
“Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 20% of our total product revenue in 2024 and collectively accounted for more than 77% of our total product revenue in 2024.”
CAH · ANIP 10-KFeb 27 '26
“We conduct business with the three major wholesalers in the U.S.: Cencora, Inc., Cardinal Health, and McKesson.”
MCK · ANIP 10-KFeb 27 '26
“We conduct business with the three major wholesalers in the U.S.: Cencora, Inc., Cardinal Health, and McKesson.”
CAH · PCRX 10-KFeb 26 '26
“We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.”
MCK · PCRX 10-KFeb 26 '26
“We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.”
CAH · GRDN 10-KMar 11 '26
“Our primary wholesale distributor relationships currently include Cardinal Health, Inc., McKesson Corporation, Smith Drug Company, and Morris and Dickson Co. L.L.C., in addition to various generic drug manufacturers.”
MCK · GRDN 10-KMar 11 '26
“Our primary wholesale distributor relationships currently include Cardinal Health, Inc., McKesson Corporation, Smith Drug Company, and Morris and Dickson Co. L.L.C., in addition to various generic drug manufacturers.”
CAH · PBYI 10-KFeb 26 '26
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
MCK · PBYI 10-KFeb 26 '26
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.”
CAH · EMBC 10-KNov 25 '25
“For example, for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.”
MCK · EMBC 10-KNov 25 '25
“For example, for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.”
CAH · CTXR 10-KDec 23 '25
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”
MCK · CTXR 10-KDec 23 '25
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”